Oxynov was founded at the Institut universitaire de cardiologie et de pneumologie de Québec with the support of all respirologists on staff.
Oxynov was founded in 2009 by two physician-researchers, François Lellouche (M.D., Ph.D.) and Erwan LHer (M.D., Ph.D.), working in the field of respiratory health and conscious of the unmet needs of clinicians. OxyNov is a company focused on clinical innovation and on the marketing of its oxygen therapy devices. Mission
Revolutionize oxygen therapy and respiratory assistance through an approach that combines medical research with technological innovation to develop a range of interrelated solutions to:
- Improve patients quality of life (efficacy and safety of treatment, keeping patients at home).
- Contribute to the effort to reduce healthcare costs.
At the beginning of 2017, OxyNov will target the European hospital market with FreeO2, a unique solution that revolutionizes oxygen therapy, the treatment most frequently administered in hospitals.
- Ten clinical studies involving over 400 hospital patients in Canada and France demonstrated the benefits of FreeO2 for patients and for the healthcare system, including shorter hospital stays.
- FreeO2 is protected by a U.S. patent.